Imidazole-based sphingosine-1-phosphate transporter Spns2 inhibitors

Area of Science:

• Biochemistry
• Immunology
• Medicinal Chemistry

Background:

• Sphingosine-1-phosphate (S1P) is a lipid mediator crucial for immune cell trafficking.
• S1P gradients guide lymphocyte egress from lymphoid tissues.
• S1P transporter (Spns2) inhibitors are being investigated to modulate immune cell movement.

Purpose of the Study:

• To explore structure-activity relationships (SAR) of Spns2 inhibitors.
• To investigate imidazole as a linker and positive charge surrogate in Spns2 inhibitors.
• To identify novel Spns2 inhibitors with potential therapeutic applications.

Main Methods:

• Synthesis of novel compounds incorporating imidazole into the SLF1081851 scaffold.
• In vitro assessment of Spns2-dependent S1P transport inhibition in HeLa cells.
• Determination of IC50 values for compound efficacy.

Main Results:

• Compound 7b demonstrated potent inhibition of Spns2-dependent S1P transport with an IC50 of 1.4 ± 0.3 µM.
• Imidazolium moieties can serve as effective substitutes for the terminal amine in SLF1081851.
• Spns2 inhibition efficacy is significantly influenced by the length of the S1P lipid alkyl tail.

Conclusions:

• Imidazole incorporation represents a viable strategy for developing Spns2 inhibitors.
• The identified compounds offer a new scaffold for modulating S1P transport.
• Further research into Spns2 inhibitors could lead to novel immunomodulatory therapies.